G. Dai

发表

Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia

A. Blackwood-Chirchir, M. Pfister, A. Roy, 2008, Journal of clinical pharmacology.

Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase

G. Marcucci, Kenneth K. Chan, Zhongfa Liu, 2008, Drug Metabolism and Disposition.

rs10865710 polymorphism in PPARG promoter is associated with the severity of type 2 diabetes mellitus and coronary artery disease in a Chinese population

Yongyan Song, G. Dai, Liang Liu, 2021, Postgraduate Medical Journal.

Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry

G. Marcucci, Kenneth K. Chan, Zhongfa Liu, 2008, The AAPS Journal.

Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry.

G. Marcucci, Shujun Liu, Kenneth K. Chan, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Application of LC-MS for quantitative analysis and metabolite identification of therapeutic oligonucleotides.

G. Dai, Wenkui Li, Z. Lin, 2007, Journal of pharmaceutical and biomedical analysis.

A Specific Picomolar Hybridization-Based ELISA Assay for the Determination of Phosphorothioate Oligonucleotides in Plasma and Cellular Matrices

G. Marcucci, Kenneth K. Chan, W. Blum, 2006, Pharmaceutical Research.

General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade — a single-center retrospective study

Zhuoli Zhang, G. Dai, Juan Li, 2015, Clinical Rheumatology.

Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G 3139 in Cultured Cells and Treated Patientswith AcuteMyeloid Leukemia

M. Caligiuri, M. Grever, J. Byrd, 2005 .

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

C. Bloomfield, M. Grever, J. Byrd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.

M. Caligiuri, C. Bloomfield, M. Grever, 2003, Blood.

Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia

M. Caligiuri, M. Grever, J. Byrd, 2005, Clinical Cancer Research.

Promotes Gene Expression by Disrupting the DNA Binding of the AML1/ETO and HDAC1 Repressor Complex.

G. Marcucci, T. Shen, D. Perrotti, 2004 .

G3139, a BCL-2 antisense oligo-nucleotide, in AML.

M. Caligiuri, M. Grever, J. Byrd, 2004, Annals of hematology.

High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2

Yilong Zhang, Zhongfa Liu, D. Benbrook, 2006, Cancer Chemotherapy and Pharmacology.